slides · global inventory
Disclaimer
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,127
Current window 30,181-30,210
Pages 1,371
Rows per page 30
Component
30,181-30,210 of 41,127
02
argenx SE | Results Presentation Deck | 15 slidesargenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Setup1 hit
07
This is a standard pharmaceutical product information slide.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations 1 hit
13
The slide uses a pyramid layout to categorize indications by prevalence size, with green dots indicating successful proof-of-concept or Phase 3 data.argenx SE | Results Presentation Deck | 15 slides · argenx
Conference presentation Investor relations Beat · Market Sizing1 hit
02
Aston Martin Lagonda | Investor Day Presentation Deck | 66 slidesAston Martin Lagonda | Investor Day Presentation Deck | 66 slides · Aston Martin
Conference presentation Investor relations 1 hit
02
AstraZeneca | Investor Event Presentation Deck | 52 slidesAstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
06
The slide uses a combination of stacked bar charts for revenue composition and a horizontal bar chart for growth metrics.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
09
The diagram illustrates a hub-and-spoke model where the central hub is 'Diverse portfolio for combinations' and the spokes are the various therapeutic areas.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
10
The slide uses a timeline framework to highlight key clinical trial milestones.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
14
Includes Kaplan-Meier survival curve and 'number at risk' table.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
15
Clinical trial data visualization (Kaplan-Meier plot).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
19
Slide 20 of a presentation; includes technical definitions and study references in the footer.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
21
The slide uses a three-column layout to explain the product, the strategy, and the clinical trial pipeline.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
23
Includes clinical trial abbreviations and definitions in the footer.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
24
The chart is a diverging stacked bar chart comparing two treatment arms. Yellow boxes highlight specific hematological toxicities.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
25
The slide uses a process flow diagram to map clinical trials to strategic goals.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · SatisfactionLoop · Before After1 hit
26
Includes spider plot (target lesion change over time) and waterfall plot (best percentage change).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
28
The slide uses a matrix structure to segment the market by disease stage and molecular profile, overlaying clinical trial names (e.g., AEGEAN, FLAURA) as product markers.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
32
Clinical trial data presentation showing PFS outcomes for Arm 1 (chemo + bev) vs Arm 3 (chemo + bev + durvalumab + olaparib).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
37
The slide outlines a basket trial design for Enhertu across multiple solid tumor types.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
39
The slide includes a summary table at the bottom showing Median Duration of Response (DoR) for the three patient cohorts.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
40
The chart is a classic waterfall plot used in oncology clinical trials to visualize tumor shrinkage.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
41
The chart uses a grouped bar structure to compare IHC 3+ and IHC 2+ prevalence ranges across 8 cancer types.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
43
The slide illustrates the process of reweighting the ASCEND trial population to match the ALPINE trial population for a fair comparison.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
44
The slide uses a Kaplan-Meier curve for PFS and a forest plot for safety odds ratios.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
46
The slide uses a column-based layout to map specific drug brands and pipeline assets to five major oncology therapeutic areas.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
48
The slide uses a matrix-like structure to align patient segments (rows) with treatment stages (columns) and specific clinical trials (cells).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
49
The slide uses a matrix-like layout to map clinical trials (e.g., SERENA-4, CAPItello291) against disease stages and risk profiles.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
51
The slide uses a standard clinical trial flow diagram (randomization, intervention, surgery, follow-up).AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
52
The slide uses bar charts to compare clinical trial data against historical SoC benchmarks. Right chart excludes pancreatic cohort due to small sample size.AstraZeneca | Investor Event Presentation Deck | 52 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
02
Azek | Results Presentation Deck | 19 slidesAzek | Results Presentation Deck | 19 slides · The AZEK Company
Conference presentation Investor relations Beat · Humble Origins1 hit